摘要
目的观察氯吡格雷联合阿司匹林治疗进展性脑卒中的安全性及有效性,为进展性脑卒中的临床治疗提供依据。方法回顾性分析130例进展性脑卒中患者,分为氯吡格雷联合阿司匹林治疗组(治疗组)、单用阿司匹林治疗组(对照组),比较2组入院时、进展后、治疗14d后的NIHSS评分及mRS评分。结果治疗组治疗14d后NIHSS评分较对照组明显下降,mRS评分较对照组显著提高,差异均有统计学意义(P<0.05),2组不良反应相比,差异无统计学意义(P>0.05)。结论对进展性脑卒中患者采用双抗血小板治疗效果明显,能有效提高疗效及日常生活能力,且安全性较高。
Objective To observe the safety and efficacy in the treatment of stroke in progression (SIP) by clopldogrel combining with aspirin, and to provide evidence for clinical treatment of SIP. Methods Totally 130 SIP patients were retrospectively analyzed. The patients were divided into two groups, the group treated by clopidogrel combining with aspirin (treatment group), and the one by merely aspirin (control group). The two groups were compared in terms of NIHSS score and mRS score in three periods-when they just came to the hospital,began to receive treatment,and 14 days after they were treated. Results After treat-ment, comparing with control group, the NIHSS score of treatment group after 14 days decreased obviously, while mRS score increased significantly. The two differences of the two groups were of statistical significance (P〈0. 05). However, adverse reaction among the two therapy was of no statistical significance(P〉0.05). Conclusion Dual antiplatelet therapy is effective in the treat- ment of SIP,which can improve the efficacy and patients" daily living ability. What's more, it is of good safety.
出处
《中国实用神经疾病杂志》
2017年第21期27-29,共3页
Chinese Journal of Practical Nervous Diseases
基金
广东省医学科学技术研究基金项目(No.B201511)